Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

In participants with atypical <i>EGFR</i>-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-12-01
DOI
https://doi.org/10.1200/jco-24-02835
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

Adriano Gravina, Leonardo Trani, Giuseppe Curigliano, Craig S. Meyer et al.
Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
article

Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

Adriano Gravina, Leonardo Trani, Giuseppe Curigliano, Craig S. Meyer, Shun Lu, Melina E. Marmarelis, Benjamin Besse, Joel W. Neal, Jiuwei Cui, Kōichi Goto, Sebastian Yves Friedrich Michels, Roland E. Knoblauch, Alexander I. Spira, Pilar Garrido, Isabelle Leconte, Luis Paz‐Ares, Frank Griesinger, James Chih‐Hsin Yang, Matthew A. Gubens, Christina S. Baik, Pascale Tomasini, Mahadi Baig, Minglei Zhuo, Joshua Bauml, Xiaorong Dong, Levon Demirdjian, Eric B. Haura, Byoung Chul Cho, Se‐Hoon Lee, Patricia Lorenzini, Jorge J. Nieva, Gianluca Del Conte, Niels Reinmuth, Gee‐Chen Chang, Yuki Sato, Zacharias Anastasiou, Marcel Wiesweg, Nicolas Girard, Lin Wu, Enriqueta Felip, Meili Sun, Yongsheng Wang, Yongsheng Li, Yongsheng Li, Jong‐Seok Lee, Yiping Zhang, Se Hyun Kim, Sophie Cousin, Youyi Zhang, Joshua C. Curtin, James Mahoney, Dong-Wan Kim, Xuesong Lyu, Yu Yao
article en

Abstract

In participants with atypical <i>EGFR</i>-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.

Journal of Clinical OncologyVol. 44(1)
Hebron University (PS), Universitat Autònoma de Barcelona (ES), Centre National de la Recherche Scientifique (FR), Johnson & Johnson (United States) (US), Central South University (CN), Inserm (FR), Chongqing University (CN), National Taiwan University (TW), Yonsei University (KR), Jilin University (CN), University of Washington (US), Aix-Marseille Université (FR), Sichuan University (CN), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Johnson & Johnson (Switzerland) (CH), Düsseldorf University Hospital (DE), Fred Hutch Cancer Center (US), Integrated Oncology (United States) (US), Zhejiang Cancer Hospital (CN), Okayama University Hospital (JP), Vall d'Hebron Institut de Recerca (ES), Hunan Cancer Hospital (CN), Sichuan Cancer Hospital (CN), Virginia Cancer Specialists (US), First Hospital of Jilin University (CN), Vall d'Hebron Hospital Universitari (ES), Johnson Electric (China) (CN), National Cancer Center Hospital East (JP), University Hospital Cologne (DE), Chongqing Cancer Hospital (CN), Hôpital de la Timone (FR), Heinrich Heine University Düsseldorf (DE), University of Pennsylvania (US), Sungkyunkwan University (KR), Stanford University (US)
Openalex Percentile: Top 44%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.